A 72-year-old man with metastatic castration-resistant prostate cancer (mCRPC) who has progressed on leuprolide and bicalutamide combination therapy is now being considered for next-line hormonal therapy. Which agent is the preferred choice for this patient?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.